{Reference Type}: Journal Article
{Title}: Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer.
{Author}: Janssen JBE;Medema JP;Gootjes EC;Tauriello DVF;Verheul HMW;Janssen JBE;Medema JP;Gootjes EC;Tauriello DVF;Verheul HMW;Janssen JBE;Medema JP;Gootjes EC;Tauriello DVF;Verheul HMW;
{Journal}: Cancer Treat Rev
{Volume}: 109
{Issue}: 0
{Year}: Sep 2022
{Factor}: 13.608
{DOI}: 10.1016/j.ctrv.2022.102433
{Abstract}: RAS genes are the most frequently mutated oncogenes in cancer. These mutations occur in roughly half of the patients with colorectal cancer (CRC). RAS mutant tumors are resistant to therapy with anti-EGFR monoclonal antibodies. Therefore, patients with RAS mutant CRC currently have few effective therapy options. RAS mutations lead to constitutively active RAS GTPases, involved in multiple downstream signaling pathways. These alterations are associated with a tumor microenvironment (TME) that drives immune evasion and disease progression by mechanisms that remain incompletely understood. In this review, we focus on the available evidence in the literature explaining the potential effects of RAS mutations on the CRC microenvironment. Ongoing efforts to influence the TME by targeting mutant RAS and thereby sensitizing these tumors to immunotherapy will be discussed as well.